Research Article

Efficacy of Diosmectite (Smecta)® in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Faouzi Khediri,1 Abdennebi Ilhem Mrad,2 Moussadek Azzouz,3 Hedi Doughi,4 Taoufik Najjar,5 Hélène Mathiex-Fortunet,6 Philippe Garnier,6 and Antoine Cortot7,8

1 83 avenue Mohamed V, 1002 Tunis, Tunisia
2 Regional Hospital, Route Mornag—Yasmine, 2013 Ben Arous, Tunisia
3 Tahar Mammouri Regional Hospital, 8000 Nabeul, Tunisia
4 Interior Security Forces Hospital, 2670 La Marsa, Tunisia
5 Charles Nicolle Hospital, Boulevard du 9 avril, 1006 Tunis, Tunisia
6 Ipsen, 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France
7 Univ Lille Nord de France, F-59000 Lille, France
8 CHU Lille, F 59000 Lille, France

Correspondence should be addressed to Antoine Cortot, antoine.cortot@chru-lille.fr

Received 1 February 2011; Revised 29 March 2011; Accepted 27 April 2011

Academic Editor: A. Castells

Copyright © 2011 Faouzi Khediri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although diosmectite has demonstrated efficacy in the treatment of acute watery diarrhoea in children, its efficacy in adults still needs to be assessed. The objective of this study was therefore to assess the efficacy of diosmectite on the time to recovery in adults with acute diarrhoea.

Methods. A total of 346 adults with at least three watery stools per day over a period of less than 48 hours were prospectively randomized to diosmectite (6 g tid) or placebo during four days. The primary endpoint was time to diarrhoea recovery.

Results. In the intention-to-treat population, median time to recovery was 53.8 hours (range [3.7–167.3]) with diosmectite (n = 166) versus 69.0 hours [2.2–165.2] with placebo, (n = 163; P = .029), which corresponds to a difference of 15.2 hours. Diosmectite was well tolerated.

Conclusion. Diosmectite at 6 g tid was well tolerated and reduced the time to recovery of acute watery diarrhoea episode in a clinically relevant manner.

1. Introduction

Acute diarrhoea is one of the leading causes of morbidity worldwide [1]. The annual rate of diarrhoea among adults in Western Europe and the United States averages about one episode per person per year [2–4]. Episodes are usually brief, not life-threatening and most often self-limited but symptoms can be disturbing and incapacitating. Urgency, loose stools, abdominal discomfort, and inconvenience such as loss of faecal continence make it an unpleasant and distressing condition. It is commonly recognized that these symptoms lead to substantial costs for society as it is estimated that half of the episodes are related to missed workdays [5, 6].

Various guidelines are available for the treatment of acute diarrhoea in adults [6–8]. Fluid intake is to be maintained, preferably with glucose-containing drinks or electrolyte-rich soup, as indicated by thirst. Oral rehydration solutions are needed in frail people only. Small light meals can be recommended, solid food intake being guided by appetite. Several treatment options are available: antidiarrhoeal therapies such as antimotility, anticholinergic, antisecretory, and antimicrobial drugs, as well as adsorbents.

Diosmectite, an activated natural aluminosilicate clay consisting of a double aluminium and magnesium silicate, is an adsorbent widely used for the treatment of acute infectious diarrhoea in children. In children, diosmectite efficacy in the treatment of acute watery diarrhoea has been assessed in a recent meta-analysis. Combined data from six randomized, controlled trials have shown that diosmectite significantly reduces diarrhoea duration by one day and increases the chance of recovery on intervention day three.
versus control group [9]. Two recent trials have indicated that diosmectite reduces stool output (versus placebo) in children with acute watery diarrhoea [10].

In adults, no prospective, randomized, placebo-controlled trial on the efficacy of diosmectite in the treatment of acute diarrhoea has yet been conducted. Diosmectite was compared to loperamide only, in four open, prospective trials that showed similar effects for both drugs in the treatment of acute infectious diarrhoea [11–14]. The clinical effect of diosmectite has nonetheless been studied in functional diarrhoea [15, 16], radiation-induced diarrhoea [17], irinotecan-induced diarrhoea [18], and AIDS-associated chronic idiopathic diarrhoea [19].

Like other adsorbents, diosmectite is not absorbed in the intestine. It can adsorb eight times its own weight of water, thereby diminishing free stool water. It also adsorbs toxins, bacteria, and rotavirus, preventing their adherence to intestinal membranes. Diosmectite strengthens the mucosal barrier, and, in the absence of mucus, prevents its disruption [20–22]. By consequence, on the contrary to some anti diarrhoeal agents acting on motility, diosmectite could decrease the time infectious agents remaining in the intestine. However the absorbing characteristics of diosmectite can disturb the absorption rates of other substances. Therefore, the concomitant use of other medicinal products is not recommended. Furthermore, this pharmacological profile is accompanied by a good safety profile [9].

This demonstrated efficacy in children suggests that, compared to placebo, diosmectite could improve recovery from acute watery diarrhoea in adults, but this has never been studied. We therefore undertook a multicentre, randomized, double-blind, placebo-controlled trial to assess the efficacy of diosmectite for the treatment of acute watery diarrhoea in adults.

2. Materials and Methods

2.1. Patients. The study included outpatient males and nonpregnant women aged 18 to 65 years in 23 primary and secondary care centres in Tunisia.

Inclusion criteria were an acute diarrhoea episode defined as at least three watery stools per day over a period of 48 hours or less, and patients with usually normal bowel movements, that is, at least three normal stools per week and three or less normal stools per day.

Exclusion criteria related to the diarrhoea episode were fever >39°C, blood or pus in stools, previous history of acute watery diarrhoea over the past 30 days, dehydration requiring intravenous rehydration, traveller’s diarrhoea, history of chronic diarrhoea (three or more loose or watery stools per day for at least 12 weeks, consecutive or not, in the preceding 12 months), and motor diarrhoea defined as urgent, morning postprandial need for defaecation. Exclusion criteria related to drug use were patients having used anti diarrhoeal agents over the month prior to baseline, patients requiring the daily intake of a drug treatment with narrow therapeutic margin, and patients with diarrhoea possibly induced by antibiotics, laxative agents, thyroid hormones, or colchicine.

2.2. Study Design. This was a multicentre, placebo-controlled, double-blind, randomized study with parallel groups conducted in 23 centres in Tunisia. Tunisia was chosen for its good medical practice and compliant organization and its prevalence of acute infectious diarrhoea comparable to that of industrialized countries [4, 23].

Newly diagnosed ambulatory patients suffering from acute diarrhoea presumed to be of infectious origin were randomized to receive diosmectite or placebo. During their participation, patients recorded in diaries their stool frequency, presence of blood in stools, and abdominal pain/cramps. An acute diarrhoea episode was regarded to have resolved after the patient had one formed stool followed by a non watery stool.

The study was registered at http://www.clinicaltrials.gov/ under the reference NCT00276328. The study was conducted in accordance with the declaration of Helsinki (Somerset West, Republic of South Africa, October 1996), with the Tunisian regulatory texts relative to the protection of persons participating in biomedical research, and with the applicable Good Clinical Practices requirements (USFDA 21CFR-1A part 50 subpart D concerning children in clinical investigations; European Clinical Trials Directives 2001/20/EC and 2005/28/EC, corresponding to ICH E6). The Independent Ethics Committee of Tunis, Tunisia, approved the study protocol in January 2005. Patients gave their informed consent before inclusion.

2.3. Treatment. Patients were randomly treated with either diosmectite or placebo. Patients were randomized at visit 1, in sequential ascending order within each centre. The investigator only dispensed the study drug to the patients included in the study. For each study site, the sponsor-assigned biostatistician prepared a list of treatment allocation codes, which were confidentially supplied to the drug supplier. The master list and the copy given to the Clinical Trial Supplies Unit were kept confidential in a safe and secure location. The randomization list was not released until approval was received for the study to be unblinded for analysis. For both diosmectite and placebo, treatment was two sachets each containing 3 g of powder for oral suspension three times a day (morning, lunch and dinner). From day 1 to day 4, the treatment was mandatory (i.e., six sachets per day). From day 5, the dose was six sachets per day until recovery, that is, one formed stool followed by a nonwatery stool, with a maximum of seven days of treatment.

Diosmectite is a powder for oral suspension in a sachet, composed of 3.000 g diosmectite, 0.004 g vanillin, 0.007 g sodium saccharin, and 0.749 g glucose monohydrate. A placebo formula was specifically developed. It was a powder for oral suspension in a sachet, composed of 1.000 g titanium dioxide, 1.181 g maltodextrin (Roquette Glucidex IT 38), 0.004 g vanillin, 0.007 g sodium saccharin, 2.150 g glucose monohydrate, and 0.018 g caramel colouring E150B. Placebo was inert and identical to diosmectite in size, weight, colour, smell, taste, and appearance, either as a powder or a water solution. Its absence of pharmacological activity was demonstrated on an animal model of watery diarrhoea (data not shown). Treatment compliance was assessed at visit 2.
or 3, based on sachet consumption recorded in the patient diary, overall count of used and unused sachets, and answers to questions on study drug compliance.

2.4. Procedures. Patients attended the study centres three times: at screening (patients included in the study began treatment at once), at midstudy (day 4 or 5 after inclusion), and for a concluding examination (day 8 or 9 after inclusion).

At baseline visit (visit 1), written informed consent was collected, patients were given a diary, and the following data were collected: demographics, vital signs, weight, physical examination results, use of concomitant medication, previous medical history, and case history of the acute diarrhoea episode including date of first watery stool, number of stools over the past 24 hours, and presence of other associated symptoms over the past 24 hours (nausea, abdominal pain, anal irritation). Patients were asked to record the following data every day in the diary: date, hour of stool onset, stool consistency (watery, loose, formed, or hard), presence of symptoms such as nausea, abdominal pain, and anal irritation, and study drug consumption (number of sachets taken each day). To standardize the rating of stool consistency, patients were shown a scheme explaining the different stool consistencies and corresponding ratings [24]. A stool was sampled for microbiological and parasitic examination at baseline.

During the second and the third visits (visit 2 and visit 3), investigators collected vital signs, physical examination, weight, adverse events, clinical data, study drug use in the diary, stool consistency, and stool time. In addition, the number of treatment sachets used and unused that were kept by the investigator was recorded at visit 3.

2.5. Objectives. The primary objective was to compare the efficacy of diosmectite to that of placebo in adults with acute watery diarrhoea, taking time to recovery as a primary endpoint. The secondary objectives were to compare diosmectite and placebo with regards to the other efficacy parameters and safety in adults with acute watery diarrhoea.

2.6. Primary Outcome Measure. Time to recovery was defined as the time (hours) from first study drug intake (H0) to diarrhoea recovery. Recovery was defined as the first formed or hard stool followed by a nonwatery stool. Time to recovery was determined from the data collected in diaries. However, if the diary was lost or unusable, analyses were performed from data collected in the case report form, after blind review decision.

2.7. Secondary Outcome Measures. Secondary efficacy endpoints were time (hours) from the first sachet intake to the last watery stool and, per 12-hour period, number of stools, number of watery stools, percentage of patients having recovered (defined as having achieved the primary efficacy endpoint), and percentage of patients with associated symptoms such as nausea, abdominal pain, and anal irritation.

2.8. Tolerability. The safety evaluation was carried out during the follow-up visits and was based on monitoring of any adverse event (AE) occurring from the moment patients had given informed consent to 7 days after the end of the study. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 9.1. Safety variables were the frequency of adverse events, with a special attention to incidence of nausea, abdominal pain, and anal irritation.

2.9. Statistics. Primary and secondary endpoints were compared in both groups using appropriate statistical tests: Wilcoxon’s test for quantitative parameters without normal distribution described by median and range; Student’s t-test for quantitative parameters with normal distribution described by mean and standard deviation; Mantel-Haenszel’s test, Chi-square or Fisher’s test for qualitative parameters described by frequency and percentage.

With regards to the primary endpoint, statistical analysis was based on Wilcoxon’s test in the intention-to-treat (ITT) population. The ITT population included randomized patients having taken the study drug at least once together with a primary endpoint that was assessable. Per-protocol (PP) population included ITT patients without major protocol deviations as defined after a blind review. PP analyses were supportive only. To assess robustness of the results, it was decided to perform post hoc analyses of primary efficacy data in ITT and PP populations using the “time to event” Gehan-Wilcoxon test, which takes into account censored data and their specific distributions with early events and late censures. Secondary efficacy analyses were conducted in the ITT population.

Sample size determination was based on the hypothesis that time to recovery was significantly shorter under diosmectite than under placebo (one-sided hypothesis). From previous studies, the expected difference of the primary efficacy criterion between diosmectite and placebo was 24 hours, with an estimated standard deviation (SD) of 61.7 hours. With an alpha risk of 5% and a beta risk of 20%, the number of patients to be included per group was 140 to obtain 104 “assessable” patients per group, that is, for which the primary outcome could be assessed.

Statistical analyses were performed using SAS (SAS Institute, version 8.1, North Carolina, USA).

3. Results

3.1. Patient Disposition and Characteristics. Between January 2005 and July 2006, 23 physicians assessed 346 patients for eligibility (from 1 to 52 patients per physician, mean = 15 patients per physician). A flow chart of all the screened patients (n = 346) included and randomized to receive diosmectite (n = 173) or placebo (n = 173) is shown in Figure 1. The total of the 346 included/randomized patients was evaluated for safety. A total of 329 patients constituted the ITT population. The 17 patients excluded from the 346 screened patients for ITT analysis had been invalidated during the blinded review following an on-site audit, which revealed that they might not have fully completed their diary.

Major protocol deviations were observed in 47 patients: 26 patients (15.7%) in the diosmectite group and 21 patients (12.9%) in the placebo group. These 47 patients
were excluded from ITT population to constitute the PP population ($n = 282$). The most frequent deviations in both groups were insufficient stool recording in the diary making it impossible to calculate the time to recovery ($n = 39$ deviations), lack of stool recording or of date/time of recovery ($n = 34$), poor compliance to the treatment ($n = 14$), or previous or concomitant use of forbidden treatment ($n = 5$). Of the 47 patients with major protocol deviation, 20 were patients that had not recovered by the end of the study period (i.e., seven days). In contrast, another 5 of these 47 patients had major protocol deviations due to poor observance as a consequence of early recovery.

The two treatment groups were well balanced for basic demographic data and disease history. There was no difference between groups with regards to age, gender distribution, height, and weight, previous medical history (222/329 or 67.5% of the patients had no medical history) and concomitant treatments. The baseline clinical picture of acute diarrhoea episodes was not different between both groups (Table 1).

3.2. Primary Efficacy Evaluation. In the ITT population ($n = 329$), the median [range] time to recovery was significantly shorter in the diosmectite group (53.8 hours [3.7–167.3]) than in the placebo group (69.0 hours [2.0–165.2]) when tested with Wilcoxon’s test ($P = .0294$). The difference between the two groups was 15.2 hours. The statistical significance of this effect was also evidenced by the post hoc analysis using the time-to-event Gehan-Wilcoxon test considering censored data: 56.3 hours [47.7–68.0] in the diosmectite group versus 72.2 [63.3–82.0] in the placebo group ($P = .0291$).

In the PP analysis ($n = 282$), median time to recovery was 54.5 hours [3.7–167.3] for the diosmectite group and
Table 1: Demographics, previous medical history, and characteristics of the acute diarrhoea episode.

|                                | Diosmectite N = 166 | Placebo N = 163 | P value |
|--------------------------------|----------------------|-----------------|---------|
| Demographics                   |                      |                 |         |
| Male, n (%)                    | 89 (53.6)            | 86 (52.8)       | .88a    |
| Age (years), median [range]    | 38.0 [19–63]         | 38.0 [19–66]    | .84b    |
| Height, females (cm), median [range] | 162.0 [150–180]    | 162.0 [150–182] | .74b    |
| Height, males (cm), median [range] | 172.0 [158–202]   | 173.0 [158–189] | .33b    |
| Weight, females (kg), median [range] | 64.0 [40–94]      | 66.0 [44–102]   | .29b    |
| Weight, males (kg), median [range] | 78.0 [49–107]     | 76.0 [55–152]   | .24b    |
| Characteristics of the diarrhoea episode |                      |                 |         |
| Previous history of gastrointestinal disorders, n (%) | 9 (5.4)            | 13 (8.0)        | .35a    |
| Days from the 1st watery stool to inclusion, median [range] | 1.0 [0–3]          | 1.0 [0–3]       | .90b    |
| Nausea, abdominal pain, or anal irritation, n (%) | 156 (94)           | 148 (90.8)      | .28b    |
| Number of stools over the past 24 hours, median [range] | 5.0 [2–22]         | 6.0 [3–20]      | .17b    |
| Positive stool culture, n (%) | 40 (29.2)           | 33 (22.9)       | .23a    |
| Rotavirus                      | 16 (11.9)           | 14 (10.0)       | .61a    |
| Adenovirus                     | 7 (5.4)             | 3 (2.2)         | .21a    |
| Escherichia coli               | 13 (9.6)            | 13 (9.3)        | .92a    |
| Staphylococcus aureus          | 4 (2.9)             | 2 (1.4)         | .44a    |
| Amoebiasis                     | 4 (2.9)             | 1 (0.7)         | .21a    |

2-tailed Chi-square test; Wilcoxon’s test.

Median time from first sachet intake to the last watery stool was 20.5 hours [0.0–160.8] in the diosmectite group and 23.0 hours [0.0–223.8] in the placebo group (P = .569). The median number of watery stools decreased from 2 at baseline to 0 at the 12–24 h period onwards (N.S).

Nausea during the 24 hours before inclusion was present in 71.7% of the patients in the diosmectite group and 68.7% in the placebo group. Incidence decreased dramatically to <5% in both groups after 48 hours (N.S).

Abdominal pain before inclusion was present in 86.1% of the patients in the diosmectite group and 78.5% in the placebo group. Incidence decreased to <15% in both groups after 48 hours (N.S). Anal irritation before inclusion was
present in 18.1% of the patients in the diosmectite group and 24.5% in the placebo group. Incidence decreased to <5% in both groups after 36 hours (N.S).

3.4. Safety and Tolerability. Both diosmectite and placebo were well tolerated. The median [range] duration of exposure was 4.2 days [0.3–7.5] in the diosmectite group and 4.2 days [0–10.1] in the placebo group. In total, 12 AEs occurred in 11 patients during the study: 6 AEs in 6 patients (3.5%) of the diosmectite group and 6 AEs in 5 patients (2.9%) of the placebo group. In both groups, the most frequently reported AEs were gastrointestinal disorders.

Particularly, incidence of new nausea episodes during the study was observed in 4.2% (7/166) of the patients in the diosmectite group and 3.7% (6/163) in the placebo group. Incidence of abdominal pain episodes was observed in 2.4% (4/166) of the patients in the diosmectite group and 8.6% (14/163) in the placebo group. Finally, incidence of anal irritation episodes was observed in 12.6% (21/166) of the patients in the diosmectite group and 29.4% (48/163) in the placebo group.

Two serious AEs were reported in two patients in the placebo group: one case of fracture of the lower limb and one case of appendicitis; both were assessed as unrelated to the study drug. AEs leading to permanent study medication discontinuation were reported in 3 patients in the diosmectite group (1.7%) and in 3 patients in the placebo group (1.7%). Gastrointestinal disorders (constipation, abdominal pain, appendicitis, and amoebiasis) were the main reason for discontinuation due to AEs in both groups.

During the study, no relevant abnormality was found with regards to body weight, blood pressure, and cardiac rhythm.

4. Discussion

This is the first randomized, placebo-controlled trial prospectively comparing diosmectite to placebo for the treatment of acute diarrhea in adults. This study showed that oral diosmectite sachet 6 g three times a day significantly shortened time to recovery in the treatment of acute diarrhea in adults. This was further supported by the results found in the PP population. This study also confirmed the good safety profile of diosmectite, as illustrated by the limited number of AEs, of which only 3 were considered drug related (constipation).

The statistical analysis plan was based upon the assumption that the duration of the diarrhea episode would be shorter than seven days for all patients, without any risk of data censure. It was therefore planned to compare mean diarrhea durations using the Wilcoxon’s test, which is perfectly adapted to this type of data. The definition of diarrhea duration required that patients are followed after the first formed stool to confirm the end of the diarrhea episode. This definition of recovery was selected to guarantee the clinical relevance of the primary criterion. Of note is that it was much more constraining than previous trials, which defined recovery as the first nonliquid stool. However, according to the definition of recovery used in the study, 35 patients showed diarrhea duration longer than seven days. Since the protocol planned a seven-day followup, these patients were censored in statistical analyses. Nevertheless, a post hoc time to event analysis taking data censure into account was carried out. The Gehan-Wilcoxon test was preferred to the Logrank test because of the particular distribution of the events considered and the onset of censures during study followup. Indeed, the Gehan-Wilcoxon test is more adapted than the Logrank test to early events and late censures. Moreover the latter is based upon the assumption of proportional hazards, which is most probably not verified in this trial since the active treatment is supposed to shorten time to recovery without modifying the risk of recovery. Acute watery diarrhea is self-resolving, even in the absence of treatment. The results of the Gehan-Wilcoxon test confirmed the effectiveness of diosmectite. These results are consistent with the primary analysis and confirm that diosmectite shortens time to recovery.

Despite significantly shorter time to recovery in the diosmectite group, the proportions of patients achieving recovery were similar in both groups at the end of the study. This is explained by acute watery diarrhea being self-resolving within seven days.

The trial was performed in a homogeneous Tunisian population with positive stool culture in 26% of the patients. These figures are consistent with those reported in the literature and previously in Tunisia [4, 6, 23, 25]. Of note is that most patients had a recent episode of acute diarrhea, similar in both groups (median time from first watery stool to treatment onset = 1 [0–3] day from the 1st watery stool to inclusion (NS)), with at least one associated symptom such as nausea, abdominal pain, or anal irritation in >90% of the patients and a median number of six stools per day before treatment onset. Hence, it can be extrapolated that if the primary endpoint variable had been measured from the time of onset of diarrhea, instead of from the first intake of study drug, the difference between the two groups would still have been the same, that is, 15.2 hours. Moreover, this pattern of diarrhea is in accordance with the definition of acute diarrhea in developed countries [4, 25, 26]. Therefore, it can be estimated that results of the present study can be extrapolated to western countries.

The endpoints most frequently used in trials regarding antidiarrhoal drugs in children and adults are stool volume and time from treatment onset to last liquid or first formed stool [12, 14, 26, 27]. Except in chronic diarrhea, trials performed in adults rarely use stool volume as an endpoint. The clinical effect of diosmectite as an antidiarrhoal agent in adults has been assessed mainly by the measurement of time to transit normalization [6, 26]. The definition of recovery chosen is again more stringent since it is based not only on the achievement of a normal stool but also by its following a nonwatery stool, thereby reflecting an actual cessation of the acute diarrhea episode.

The only data to which the present results may be compared derive from trials comparing diosmectite to loperamide in the treatment of acute diarrhea in adults [11–14]. However, heterogeneity in trial design, drug doses, and endpoint definition makes these results difficult to compare
with those presented here. It can only be inferred from these studies that, depending on the modalities of treatment and recovery definition, diosmectite and loperamide can show similar improvements of the duration of acute diarrhoea in adults. This is further supported by the results from the prospective trials comparing loperamide to placebo in acute diarrhoea in adults [27–30]. In one study the endpoint was the mean number of stools per day [30] but in the other three studies, the definition of time to recovery was not very different to that chosen here: time between the first drug intake and the first 24-hour period without watery or loose stool that was not followed by the recurrence of diarrhoea during the following 24–48 hours. In these three trials, median times to recovery were respectively: 45 hours 15 minutes in the placebo group versus 23 hours and 30 minutes in the 1 mg loperamide group [27]; 34 hours 15 minutes in the placebo group versus 26 hours 30 minutes in the 1 mg loperamide group [28]. This corresponds to respective decreases of 21 hours, 12 hours 40 minutes, and 7 hours 45 minutes with loperamide, which can be considered to be a similar range to the results observed here with diosmectite. In addition, the trial data presented here employed a more stringent definition of recovery. In studies comparing loperamide to placebo, time to recovery was time to the first formed or hard stool followed by a nonwatery stool whereas in the present study it was time to the first formed hard stool followed by a nonwatery stool.

5. Conclusions

This randomized, double-blind, placebo-controlled trial shows that diosmectite at a dose of 6 g three times a day reduced the time to recovery of an acute watery diarrhoea episode in adults. Diosmectite was also associated with a very good safety profile and did not decrease intestinal peristalsis. In summary, the results of the present study support the use of diosmectite in the management of acute watery diarrhoea in adults.

Conflict of Interests

H. M.-Fortunet and P. Garnier are employees of Ipsen, the developer of diosmectite and owner of Smecta. F. Khediri, A. I. Mrad, M. Azzouz, H. Doughi, and T. Najjar declare having received honoraria and/or compensation with regards to the study, as an investigator or coordinator, in relation with the time spent on the study. These authors declare no conflict of interest with regards to the present paper derived from the study, for which no compensation or stipend was received. There is no organic or regular relationship between these authors and Ipsen. These authors own no shares in Ipsen, and no member of their immediate family is employed by Ipsen.

Authors’ Contribution

F. Khediri, A. I. Mrad, M. Azzouz, H. Doughi, and T. Najjar substantially participated in data acquisition, revised the paper for important intellectual content, and approved the final version of the paper. H. M.-Fortunet and P. Garnier participated in conception, design, analysis of data, revised the paper for important intellectual content, and approved the final version of the paper. A. Cortot participated in conception, design, analysis and interpretation of data, drafted the paper, and revised it for important intellectual content, and approved the final version of the paper.

Acknowledgments

This study was sponsored by Ipsen. The authors would like to thank Dr. Guillaume Hébert from SC Partners who assisted in preparing the paper on behalf of Ipsen.

References

[1] M. Kosek, C. Bern, and R. L. Guerrant, “The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000,” Bulletin of the World Health Organization, vol. 81, no. 3, pp. 197–204, 2003.
[2] W. E. Garthright, D. L. Archer, and J. E. Kvenberg, “Estimates of incidence and costs of intestinal infectious diseases in the United States,” Public Health Reports, vol. 103, no. 2, pp. 107–115, 1988.
[3] R. L. Guerrant, J. M. Hughes, N. L. Lima, and J. Crane, “Diarrhea in developed and developing countries: magnitude, special settings, and etiologies,” Reviews of Infectious Diseases, vol. 12, supplement 1, pp. S41–S50, 1990.
[4] N. M. Thielman and R. L. Guerrant, “Acute infectious diarrhea,” New England Journal of Medicine, vol. 350, no. 1, pp. 38–47, 2004.
[5] P. Avendano, D. O. Matson, J. Long, S. Whitney, C. C. Matson, and L. K. Pickering, “Costs associated with office visits for diarrhea in infants and toddlers,” Pediatric Infectious Disease Journal, vol. 12, no. 11, pp. 897–902, 1993.
[6] D. Wingate, S. F. Phillips, S. J. Lewis et al., “Guidelines for adults on self-medication for the treatment of acute diarrhoea,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 6, pp. 773–782, 2001.
[7] S. Manatsathit, H. L. Dupont, M. Farthing et al., “Guideline for the management of acute diarrhea in adults,” Journal of Gastroenterology and Hepatology, vol. 17, supplement 1, pp. S54–S71, 2002.
[8] WHO diarrhoeal Disease Control Program, “Drugs in the management of acute diarrhoea in infants and young children,” Report WHO/CDD/CMT/86.1, 1986.
[9] H. Szajewska, P. Dziechciarz, and J. Mrukowicz, “Meta-analysis: smectite in the treatment of acute infectious diarrhoea in children,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 2, pp. 217–227, 2006.
[10] C. Dupont, J. L. K. Foo, P. Garnier, N. Moore, H. Mathieux-Fortunet, and E. Salazar-Lindo, “Oral diosmectite reduces stool output and diarrhoea duration in children with acute watery diarrhea,” Clinical Gastroenterology and Hepatology, vol. 7, no. 4, pp. 456–462, 2009.
[11] N. De Sola Pool, K. Loehle, A. J. Radzik, and J. Kinsley, “A comparison of nonsystemic and systemic anti diarrheal agents in the treatment of acute nonspecific diarrhea in adults,” Today’s Therapeutic Trends, vol. 5, no. 2, pp. 31–38, 1987.
[12] H. L. DuPont, C. D. Ericsson, M. W. DuPont, A. C. Luna, and J. J. Mathewson, “A randomized, open-label comparison of non-prescription loperamide and attapulgite in the symptomatic treatment of acute diarrhea,” *American Journal of Medicine*, vol. 88, no. 6, pp. 205–235, 1990.

[13] W. Leber, “A new suspension form of smectite (Liquid “Diasorb”) for the treatment of acute diarrhoea: a randomized comparative study,” *Pharmatherapeutica*, vol. 5, no. 4, pp. 256–260, 1987.

[14] Y. M. Van Maercke and M. Mallend, “Comparative clinical trial of Diasorb and loperamide in acute diarrhea in adults,” *Tijdschrift Voor Gastro-Enterologie*, vol. 17, pp. 367–371, 1987.

[15] F. Y. Chang, C. L. Lu, C. Y. Chen, and J. C. Luo, “Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome,” *Journal of Gastroenterology and Hepatology*, vol. 22, no. 12, pp. 2266–2272, 2007.

[16] Y. Yao-Zong, L. Shi-Rong, and M. Delvaux, “Comparative efficacy of dioctahedral smectite (Smecta) and a probiotic preparation in chronic functional diarrhoea,” *Digestive and Liver Disease*, vol. 36, no. 12, pp. 824–828, 2004.

[17] J. Hombrick, “Prevention of radiation-induced diarrhea by smectite. Results of a double-blind randomized, placebo-controlled multicenter study,” *Strahlentherapie und Onkologie*, vol. 176, pp. 173–179, 2000.

[18] J. Duffour, S. Gourgou, J. F. Seitz et al., “Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving campto for advanced colorectal cancer,” *Anticancer Research*, vol. 22, pp. 3727–3731, 2002.

[19] A. Mastroianni, C. Cancellieri, O. Coronado, R. Manfredi, F. Chiodo, and S. Pignatari, “Smectite in AIDS-associated chronic idiopathic diarrheaaDiomsceptite nella diarrea cronica idiopatica in corso di AIDS,” *Minerva Gastroenterologica e Dietologica*, vol. 44, no. 4, pp. 231–234, 1998.

[20] J. Fioramonti, M. J. Fargeas, and L. Bueno, “Action of T-2 toxin on gastrointestinal transit in mice: protective effect of an argillaceous compound,” *Toxicology Letters*, vol. 36, no. 3, pp. 227–232, 1987.

[21] L. Mahraoui, M. Heyman, O. Plique, M. T. Droy-Lefaix, and J. F. Desjeux, “Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-a,” *Gut*, vol. 40, no. 3, pp. 339–343, 1997.

[22] J. Moré, F. Bénazet, J. Fioramonti, and M. T. Droy-Lefaix, “Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study,” *The Histochemical Journal*, vol. 19, no. 12, pp. 665–670, 1987.

[23] C. Fendri, A. Slim, Z. Arrouji et al., “Role of Campylobacter in the etiology of diarrheas in Tunisia,” *Tunisie Medicale*, vol. 67, no. 8-9, pp. 517–520, 1989.

[24] S. J. Lewis and K. W. Heaton, “Stool form scale as a useful guide to intestinal transit time,” *Scandinavian Journal of Gastroenterology*, vol. 32, no. 9, pp. 920–924, 1997.

[25] H. L. DuPont, “Guidelines on acute infectious diarrhea in adults,” *American Journal of Gastroenterology*, vol. 92, no. 11, pp. 1962–1975, 1997.

[26] “Guidelines for the clinical evaluation of antidiarrheal drugs,” Edited by FDA US Department of Health Education and Welfare; 1977: HEW (FDA) 78: 3049.

[27] I. W. Hughes, “First-line treatment in acute non-dysenteric diarrhoea: clinical comparison of loperamide oxide, loperamide and placebo. UK Janssen Research Group of General Practitioners,” *British Journal of Clinical Practice*, vol. 49, pp. 181–185, 1995.

[28] A. Dettmer, “Loperamide oxide in the treatment of acute diarrhea in adults,” *Clinical Therapeutics*, vol. 16, no. 6, pp. 972–980, 1994.

[29] J. W. M. Dreverman and A. J. M. Van der Poel, “Loperamide oxide in acute diarrhea: a double-blind, placebo-controlled trial,” *Alimentary Pharmacology and Therapeutics*, vol. 9, no. 4, pp. 441–446, 1995.

[30] F. P. L. Van Loon, M. L. Bennish, P. Speelman, and C. Butler, “Double blind trial of loperamide for treating acute watery diarrhoea in expatriates in Bangladesh,” *Gut*, vol. 30, no. 4, pp. 492–495, 1989.